全文获取类型
收费全文 | 2779篇 |
免费 | 167篇 |
国内免费 | 78篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 212篇 |
妇产科学 | 32篇 |
基础医学 | 322篇 |
口腔科学 | 65篇 |
临床医学 | 296篇 |
内科学 | 738篇 |
皮肤病学 | 92篇 |
神经病学 | 141篇 |
特种医学 | 423篇 |
外科学 | 183篇 |
综合类 | 45篇 |
预防医学 | 134篇 |
眼科学 | 34篇 |
药学 | 107篇 |
2篇 | |
中国医学 | 2篇 |
肿瘤学 | 182篇 |
出版年
2023年 | 9篇 |
2022年 | 20篇 |
2021年 | 30篇 |
2020年 | 24篇 |
2019年 | 38篇 |
2018年 | 54篇 |
2017年 | 40篇 |
2016年 | 33篇 |
2015年 | 61篇 |
2014年 | 67篇 |
2013年 | 91篇 |
2012年 | 80篇 |
2011年 | 86篇 |
2010年 | 110篇 |
2009年 | 117篇 |
2008年 | 85篇 |
2007年 | 131篇 |
2006年 | 93篇 |
2005年 | 89篇 |
2004年 | 66篇 |
2003年 | 57篇 |
2002年 | 66篇 |
2001年 | 63篇 |
2000年 | 77篇 |
1999年 | 66篇 |
1998年 | 136篇 |
1997年 | 156篇 |
1996年 | 138篇 |
1995年 | 114篇 |
1994年 | 116篇 |
1993年 | 99篇 |
1992年 | 36篇 |
1991年 | 46篇 |
1990年 | 39篇 |
1989年 | 68篇 |
1988年 | 54篇 |
1987年 | 45篇 |
1986年 | 54篇 |
1985年 | 48篇 |
1984年 | 28篇 |
1983年 | 17篇 |
1982年 | 26篇 |
1981年 | 31篇 |
1980年 | 25篇 |
1979年 | 5篇 |
1978年 | 8篇 |
1977年 | 18篇 |
1976年 | 25篇 |
1975年 | 15篇 |
1968年 | 6篇 |
排序方式: 共有3024条查询结果,搜索用时 31 毫秒
101.
102.
103.
Gómez-Núñez M Martino R Caballero MD Pérez-Simón JA Canals C Mateos MV Sarrá J León A Solano C Moraleda JM Urbano-Ispizua A Besalduch J Miguel JS Sierra J 《Bone marrow transplantation》2004,33(5):477-482
Over a 3-year period, 145 patients ineligible for myeloablative conditioning underwent reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (SCT) from an HLA-identical sibling in a prospective study. The median age was 54 years, 88 patients were male and 61 patients were beyond the early-intermediate phase of their disease. The 100-day probability of developing grade II-IV acute graft-versus-host disease (GVHD) was 34%, and the 1-year probability of developing chronic extensive GVHD was 41%. The 1-year probabilities of transplant-related mortality (TRM), overall (OS) and progression-free survival were 20, 60 and 52%, respectively. Multivariate analyses found a better OS in: (i) patients <60 years; and (ii) recipients of a first SCT; and a higher TRM in: (i) age >60 years, (ii) recipients of a prior autologous SCT, and (iii) an ECOG performance status >1. The 1-year TRM in patients with 0 or 1 and >2 of the above-mentioned adverse prognostic factors were 17 vs 53%, respectively (P<0.001). In summary, our study shows that elderly patients have a higher TRM following an RIC protocol. However, age by itself should not preclude these RIC transplants, since TRM appears to be unacceptably high only in the presence of additional adverse factors. 相似文献
104.
Pérez-Simón JA García-Escobar I Martinez J Vazquez L Caballero D Cañizo C Mateos MV San Miguel JF 《Bone marrow transplantation》2004,33(2):183-187
In the present study, we analyze the efficacy of prophylaxis with meropenem in patients receiving a matched related donor allogeneic transplant. In total, 38 patients were sequentially treated with meropenem starting on the day of the first febrile episode (n=17, group A) vs prophylactic meropenem starting on the first day with <500/mm(3) granulocytes (n=21, group B), and maintained until resolution of fever or after granulocyte count >500/mm(3). Of these, 16 (94%) patients in group A developed fever as compared to 16 (76%) in group B (P=0.02). While only one patient in group A did not require first-line antibiotherapy, there were seven (33%) in group B who did not require it (P=0.01) since fever lasted less than 72 h. In addition, 52% patients in group B did not require second-line antibiotics as compared to 11% among patients in group A (P=0.04). In multivariate analysis prophylaxis with meropenem (HR=2.83, 95% CI (1-8.02); P=0.04) and disease status at transplant (HR for early stage=0.15, 95% CI (0.04-0.62); P=0.04) significantly influenced the development of fever. In conclusion, the current pilot study suggests that the use of prophylaxis with meropenem during the period of neutropenia in patients undergoing allogeneic transplantation favorably affects the morbidity of the procedure by reducing febrile episodes. 相似文献
105.
106.
Geoffrey M. Reed Michael C. Roberts Jared Keeley Catherine Hooppell Chihiro Matsumoto Pratap Sharan Rebeca Robles Hudson Carvalho Chunyan Wu Oye Gureje Itzear Leal‐Leturia Elizabeth H. Flanagan João Mendonça Correia Toshimasa Maruta José Luís Ayuso‐Mateos Jair de Jesus Mari Zeping Xiao Spencer C. Evans Shekhar Saxena María Elena Medina‐Mora 《Journal of clinical psychology》2013,69(12):1191-1212
107.
Sandra Rayego‐Mateos Jose Luis Morgado‐Pascual Ana Belen Sanz Adrian Mario Ramos Satoru Eguchi Daniel Batlle Janos Pato Gyorgy Keri Jesus Egido Alberto Ortiz Marta Ruiz‐Ortega 《The Journal of pathology》2013,231(4):480-494
TWEAK, a member of the TNF superfamily, binds to the Fn14 receptor, eliciting biological responses. EGFR signalling is involved in experimental renal injury. Our aim was to investigate the relationship between TWEAK and EGFR in the kidney. Systemic TWEAK administration into C57BL/6 mice increased renal EGFR phosphorylation, mainly in tubular epithelial cells. In vitro, in these cells TWEAK phosphorylated EGFR via Fn14 binding, ADAM17 activation and subsequent release of the EGFR ligands HB‐EGF and TGFα. In vivo the EGFR kinase inhibitor Erlotinib inhibited TWEAK‐induced renal EGFR activation and downstream signalling, including ERK activation, up‐regulation of proinflammatory factors and inflammatory cell infiltration. Moreover, the ADAM17 inhibitor WTACE‐2 also prevented those TWEAK‐induced renal effects. In vitro TWEAK induction of proinflammatory factors was prevented by EGFR, ERK or ADAM17 inhibition. In contrast, EGFR transactivation did not modify TWEAK‐mediated NF‐κB activation. Our data suggest that TWEAK transactivates EGFR in the kidney, leading to modulation of downstream effects, including ERK activation and inflammation, and suggest that inhibition of EGFR signalling could be a novel therapeutic tool for renal inflammation. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. 相似文献
108.
Philippe Halfon Maria Luisa Mateos Lindemann Audrey Raimondo Sophie Ravet Claire Camus Hacène Khiri Guillaume Pénaranda Mario Sideri Maria Teresa Sandri 《Archives of virology》2013,158(6):1143-1149
A new genotyping-based DNA assay (Digene LQ®) was developed recently. The primary aim was to assess the distribution of HPV types using this new assay in atypical squamous cells of undeterminate significance (ASCUS). The secondary aim was to correlate the HPV types with the severity of the disease. The study population comprised 376 ASCUS women. The women were all Hybrid Capture II (HCII) positive and were admitted in three European referral gynecology clinics between 2007 and 2010. A colposcopy with histological examination was performed in all these patients. HPV 16 was typed in 40 % of patients, HPV 18 in 7 %, and HPV 31 in 17 %, and 18 % of patients had mixed genotypes. Patients aged over 30 more often had the HPV 16 genotype than patients aged under 30 (29 % vs. 11 %, chi-square test p < 0.001). The risk of cervical intra-epithelial neoplasia of grade 2 or more (CIN2 +) when HPV 18 positive is lower than the probability associated with HPV 16 or HPV 31: 28 % vs. 58 % and 52 %, respectively (chi-square test, p = 0.005 and p = 0.05, respectively). The Digene LQ®, a new sequence-specific hybrid capture sample preparation, is fast and efficient and allows high-throughput genotyping of 18 HR HPV types by PCR compared to traditional non-sequence-specific sample preparation methods. 相似文献
109.
María Teresa Pérez‐Gracia María Luísa Mateos Lindemann María Caridad Montalvo Villalba 《Reviews in medical virology》2013,23(6):384-398
Acute hepatitis E is a very common disease in developing countries, to the point that, according to World Health Organization estimates, one third of the world's population has been exposed to HEV. It also causes outbreaks in refugee camps or after natural disasters such as floods or earthquakes. Sporadic cases of acute hepatitis have been observed in practically all European countries and other developed geographical areas, not only in travelers from endemic countries but also in people with no risk factors. But, lately, new aspects of this infection are appearing in industrialized countries such as the possibility of the disease becoming chronic in transplant patients, the immunocompromised in general, and even in patients with previous liver disease who are immunocompetent. In this comprehensive review, we summarize the current knowledge on HEV infection. Copyright © 2013 John Wiley & Sons, Ltd. 相似文献
110.
M. Luisa Antelo Ane Altuna J. José Gimeno J. Javier Ferreiro Cristina Amunárriz J. José Mateos Saioa Zalba Aitziber Alkorta José Rifón J. Luis Arroyo Amaia Uresandi J. Antonio Moreno M. Josefa Nájera Sergio Pinzón Alejandro García J. Carlos Vallejo 《Transfusion and apheresis science》2021,60(3):103130
Plerixafor (PLX) appears to effectively enhance hematopoietic stem-cell mobilization prior to autologous hematopoietic stem cell transplantation (auto-HCT). However, the quality of engraftment following auto-HCT has been little explored. Here, engraftment following auto-HCT was assessed in patients mobilized with PLX through a retrospective, multicenter study of 285 consecutive patients. Information on early and 100-day post-transplant engraftment was gathered from the 245 patients that underwent auto-HCT. The median number of PLX days to reach the stem cell collection goal (≥2 × 106 CD34+ cells/kg) was 1 (range 1–4) and the median PLX administration time before apheresis was 11 h (range 1–18). The median number of apheresis sessions to achieve the collection goal was 2 (range 1–5) and the mean number of CD34+ cells collected was 2.95 × 106/kg (range 0–30.5). PLX administration was safe, with only 2 mild and transient gastrointestinal adverse events reported. The median time to achieve an absolute neutrophil count (ANC) >500/μL was 11 days (range 3–31) and the median time to platelet recovery >20 × 103/μL was 13 days (range 5–69). At 100 days after auto-HCT, the platelet count was 137 × 109/L (range 7–340), the ANC was 2.3 × 109/L (range 0.1–13.0), and the hemoglobin concentration was 123 g/L (range 79–165). PLX use allowed auto-HCT to be performed in a high percentage of poorly mobilized patients, resulting in optimal medium-term engraftment in the majority of patients in whom mobilization failed, in this case mainly due to suboptimal peripheral blood CD34+ cell concentration on day +4 or low CD34+ cell yield on apheresis. 相似文献